Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06760481
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Advanced Solid Malignancies

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tiragolumab — DRUG
    Given by IV
  • Atezolizumab — DRUG
    Given by IV
  • Radiation Therapy — RADIATION
    Given by IV

Study Details

An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies.

Key Dates

Start date
Apr 13, 2025
Status verified
Apr 2026
Primary completion
Sep 15, 2028
Completion
Sep 15, 2030

Study Design

Enrollment
7 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PhI/PhIbP1 Tiragolumab + Atezolizumab + RadScopal XRT
    Participants will be randomized to the trial using the Clinical Trial Conduct website
  • Experimental: PhIbP2ArmA Atezolizumab + RadScopal XRT
    Participants will be randomized to the trial using the Clinical Trial Conduct website
  • Experimental: PhIbP2ArmB Tiragolumab + Atezolizumab + RadScopal XRT
    Participants will be randomized to the trial using the Clinical Trial Conduct website
  • Experimental: PhIbP2ArmC Tiragolumab + Atezolizumab
    Participants will be randomized to the trial using the Clinical Trial Conduct website

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas M. D. Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By research site
The University of Texas M. D. Anderson Cancer Center· Houston, TX

Related Studies